Allspring Global Investments Holdings LLC Grows Position in Exelixis, Inc. (NASDAQ:EXEL)

Allspring Global Investments Holdings LLC boosted its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 82.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,562,790 shares of the biotechnology company's stock after purchasing an additional 704,786 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.55% of Exelixis worth $52,884,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. FMR LLC raised its position in shares of Exelixis by 6.1% in the third quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company's stock valued at $63,891,000 after buying an additional 140,568 shares in the last quarter. Los Angeles Capital Management LLC raised its holdings in Exelixis by 124.0% in the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company's stock valued at $46,473,000 after acquiring an additional 991,494 shares in the last quarter. Two Sigma Advisers LP lifted its position in shares of Exelixis by 6.1% during the 3rd quarter. Two Sigma Advisers LP now owns 1,702,590 shares of the biotechnology company's stock valued at $44,182,000 after acquiring an additional 98,000 shares during the period. Systematic Financial Management LP grew its holdings in shares of Exelixis by 7.1% during the 3rd quarter. Systematic Financial Management LP now owns 1,168,391 shares of the biotechnology company's stock worth $30,320,000 after purchasing an additional 77,599 shares in the last quarter. Finally, Retirement Systems of Alabama increased its position in shares of Exelixis by 24.6% in the third quarter. Retirement Systems of Alabama now owns 911,497 shares of the biotechnology company's stock worth $23,653,000 after purchasing an additional 180,021 shares during the period. Institutional investors own 85.27% of the company's stock.

Exelixis Trading Up 1.5 %

NASDAQ EXEL traded up $0.51 during trading hours on Monday, hitting $35.00. 2,854,977 shares of the company's stock were exchanged, compared to its average volume of 2,601,778. The firm has a market cap of $10.00 billion, a price-to-earnings ratio of 22.44, a PEG ratio of 0.63 and a beta of 0.53. The stock has a 50-day simple moving average of $34.19 and a 200 day simple moving average of $31.01. Exelixis, Inc. has a 1-year low of $20.14 and a 1-year high of $37.59.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 22.43% and a return on equity of 20.99%. On average, sell-side analysts anticipate that Exelixis, Inc. will post 1.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on EXEL shares. Bank of America cut shares of Exelixis from a "buy" rating to a "neutral" rating and upped their price objective for the stock from $35.00 to $39.00 in a research report on Tuesday, December 17th. Brookline Capital Management started coverage on shares of Exelixis in a research report on Monday, December 23rd. They set a "buy" rating on the stock. Guggenheim restated a "buy" rating and set a $42.00 price objective on shares of Exelixis in a research report on Wednesday, February 12th. Wells Fargo & Company raised their target price on Exelixis from $32.00 to $36.00 and gave the company an "overweight" rating in a report on Wednesday, October 30th. Finally, Truist Financial boosted their price target on Exelixis from $42.00 to $43.00 and gave the stock a "buy" rating in a report on Monday, January 27th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $37.24.

Insider Transactions at Exelixis

In other news, EVP Jeffrey Hessekiel sold 60,000 shares of the company's stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the transaction, the executive vice president now directly owns 486,059 shares of the company's stock, valued at $17,823,783.53. This represents a 10.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Patrick J. Haley sold 10,000 shares of Exelixis stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $35.27, for a total transaction of $352,700.00. Following the completion of the sale, the executive vice president now directly owns 278,665 shares of the company's stock, valued at approximately $9,828,514.55. The trade was a 3.46 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.85% of the company's stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.